Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia | PNAS
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma - eBioMedicine
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options - ScienceDirect
Cancers | Free Full-Text | Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
IJMS | Free Full-Text | Do Mutations Turn p53 into an Oncogene?
Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival | Nature Communications
IJMS | Free Full-Text | The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
p53 Is the Most Frequently Mutated Gene in Cancer, but Can We Target It?
Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway: Cell
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis | Cell Death Discovery
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
Impact of TP53 mutations in Triple Negative Breast Cancer | npj Precision Oncology
Gaining insights into relevance across cancers based on mutation features of TP53 gene - ScienceDirect
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma - eBioMedicine
Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis | Nature Communications
TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types | Aging
Survival of patients with p53 mutations in the DNA-binding motifs... | Download Scientific Diagram
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
